Analysts Set Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Target Price at $18.25

Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) have been assigned a consensus rating of “Moderate Buy” from the nine brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $18.25.

Several research firms have commented on ADPT. Morgan Stanley initiated coverage on Adaptive Biotechnologies in a research note on Monday, December 1st. They set an “equal weight” rating and a $21.00 price objective for the company. Piper Sandler set a $21.00 target price on Adaptive Biotechnologies in a research report on Friday, February 6th. JPMorgan Chase & Co. lifted their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. Wall Street Zen cut Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Guggenheim increased their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, January 26th.

Insider Buying and Selling at Adaptive Biotechnologies

In related news, COO Julie Rubinstein sold 19,060 shares of the business’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $13.83, for a total transaction of $263,599.80. Following the transaction, the chief operating officer directly owned 481,906 shares in the company, valued at approximately $6,664,759.98. The trade was a 3.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Sharon Benzeno sold 63,103 shares of the company’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total transaction of $831,066.51. Following the sale, the insider directly owned 272,751 shares of the company’s stock, valued at approximately $3,592,130.67. This represents a 18.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 2,422,544 shares of company stock valued at $35,397,620. 6.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ADPT. Rockefeller Capital Management L.P. increased its holdings in shares of Adaptive Biotechnologies by 50.7% in the fourth quarter. Rockefeller Capital Management L.P. now owns 7,577 shares of the company’s stock valued at $123,000 after purchasing an additional 2,550 shares during the last quarter. Corient Private Wealth LLC boosted its stake in Adaptive Biotechnologies by 3.4% during the fourth quarter. Corient Private Wealth LLC now owns 71,908 shares of the company’s stock worth $1,168,000 after buying an additional 2,347 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Adaptive Biotechnologies during the fourth quarter worth $28,000. T. Rowe Price Investment Management Inc. purchased a new stake in Adaptive Biotechnologies in the 4th quarter valued at $51,000. Finally, Invesco Ltd. grew its holdings in Adaptive Biotechnologies by 248.8% in the 4th quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock valued at $50,468,000 after buying an additional 2,216,595 shares in the last quarter. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Adaptive Biotechnologies Price Performance

NASDAQ:ADPT opened at $12.41 on Thursday. The company has a 50-day moving average of $15.85 and a 200 day moving average of $15.91. Adaptive Biotechnologies has a 1-year low of $6.68 and a 1-year high of $20.76. The firm has a market cap of $1.91 billion, a PE ratio of -31.02 and a beta of 2.19.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. The business had revenue of $71.68 million during the quarter, compared to analysts’ expectations of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The company’s quarterly revenue was up 51.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.23) earnings per share. Sell-side analysts anticipate that Adaptive Biotechnologies will post -0.92 EPS for the current fiscal year.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.